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A SURVEY OF PUBLIC HOSPITAL PHARMACISTS 
IN SINGAPORE ON THEIR VIEWS ABOUT
‘THE FORMULARY’ AND ITS
DECISION-MAKING PROCESS
Roy A, Li SC
National University of Singapore, Singapore, Singapore
OUR PREMISE: If the expectation is “A formulary must
help control drug costs but not just promote cheap drugs
(i.e., compromise on quality of care)”, there clearly exists
a need for pharmacoeconomics in formulary decision-
making. OBJECTIVES: To understand if such expecta-
tion and need exist in Singapore, and how confident
pharmacists would be if asked to use pharmacoeconom-
ics to aid their decision-making. METHOD: After having
obtained consent from the respective pharmacy manag-
ers, survey forms were circulated to all pharmacists in the
5 major public hospitals of Singapore. If after 2–3 weeks,
the response rate was lower than 50% a reminder (via
e-mail) and a second circulation of the questionnaire was
made. In the event of any clarification(s) being required,
the respondent was contacted over phone. RESULTS
AND CONCLUSION: With a response rate that ranged
from 50% to 85% in the individual hospitals and an
overall average of 64% (70 of 110 identified pharma-
cists responded) our findings delineated the following
picture in Singapore. Formulary restriction is the best
method to control drug costs (57%). However, it should
not be a list of cheapest alternatives (90 %) but should
ideally promote the use of the best drug (71%) while also
controlling the hospital budget (57%). Though what fac-
tors are involved in the current formulary decision-mak-
ing process are not known (49% have no knowledge),
drug effectiveness (64%) as opposed to acquisition cost
(5%) will be considered as the most important factor by
the pharmacists if they were to decide on the formulary.
However, only 1% felt very confident about being able to
use pharmacoeconomics to aid their decision-making, if
asked to do so. There is therefore, a definite but unstated
need for use of pharmacoeconomics in the formulary set-
ting; however, there is clearly a lack of capability to fulfill
the need.
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THE VALUE OF VARIOUS FORMS OF EVIDENCE 
IN DRUG FORMULARY DECISION MAKING
Morris L1, Aikin K2
1Louis A. Morris & Associates, Dix Hills, NY, USA; 2Food and 
Drug Administration, Rockville, MD, USA
INTRODUCTION: The study examined the perceived
value of different forms of evidence (i.e., randomized
controlled trials and retrospective cohort analyses study
designs) among physicians and pharmacists (N  780).
Research participants read three abstracts (for each of
three fictitious drugs) that varied type of claim (cost,
cost-effectiveness, and effectiveness) and study design.
They rated the perceived value of the study in determin-
ing formulary recommendations on seven items. METH-
ODS: Factor analysis was used to derive weights for a
single measure of value that ranged from 0.735 (low
value) to 5.145 (high value). RESULTS: Four-way ANO-
VAs indicated that cost-effectiveness (mean  3.19) and
effectiveness (mean  3.11) data were of more value than
cost data (mean  2.84, p  .0001). Also, formulary-
affiliated physicians (mean  3.10) found the studies to
be of more value than hospital pharmacy directors (mean 
2.93, p  .02). A significant two-way interaction indi-
cated that pharmacy directors valued retrospective co-
hort analyses more than randomized trials regardless of
type of claim. In contrast, physicians valued randomized
trials more than retrospective cohort analyses (p  .001).
Manipulation checks indicated some difficulty identifying
the purpose of individual studies. While most respon-
dents could correctly identify cost-effectiveness and effec-
tiveness studies (between 77% and 92% correctly identi-
fied these studies), there was confusion regarding cost
studies. Almost half of the participants (between 42%
and 57%) characterized these studies (which were de-
scribed as “cost-minimization” analyses) as cost-effec-
tiveness studies. Pharmacy directors (49%) were more
likely to mischaracterize the cost-minimization studies
compared to the physician groups (approximately 40%
of these groups) (chi square  20.29, p  .02). CON-
CLUSIONS: The results suggest that the multidisci-
plinary make-up of formulary committees is important to
assure the incorporation of multiple forms of evidence in
decision-making. Also, more attention to the study design
is essential to evaluate the value of various forms of evi-
dence for formulary decisions.
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PATIENT OUTCOMES IN THE SEDATED 
ICU PATIENT
Kamath T1, Hopefl A2, Chaikledkaew U1, Johnson KA1
1University of Southern California, Los Angeles, CA, USA; 
2AmeriNet, St. Louis, MO, USA
OBJECTIVE: This study compares patient outcomes in
the mechanically ventilated ICU patient by patient demo-
graphics, hospital characteristics and drug therapy. METH-
ODS: Data collected from 42 hospitals included patient
demographics, disease severity, sedatives/analgesics ad-
ministered, hospital type/size, days hospitalized and dis-
charge status. RESULTS: 622 patients were studied (48%
female, mean APACHE score  21.7, 31% with care
plans). Only 50% of patient episodes for ICU sedation
greater than 24 hours were treated with lorazepam
(guideline recommended drug for long-term sedation).
94% of patients received recommended analgesics. Pa-
tients in community hospitals had fewer ICU days (9.31
versus 11.05) and total hospital days (14.14 versus
16.96) compared to teaching hospitals. Patients receiving
midazolam or orazepam had shorter hospital stays (13.7
and 15.5 days respectively) compared to propofol pa-
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tients. Patients receiving midazolam had higher mortal-
ity rates (31.7%) compared to patients on lorazepam
(29.2%). However, these results were not confirmed
when controlling for disease severity and other factors.
Multivariate regression analysis revealed that type of sed-
ative/analgesic drug treatment and whether the hospital
had a care plan were not associated with shorter ICU and
total hospital stays when controlling for patient demo-
graphics and disease severity. In fact, patients admitted to
hospitals with care plans had longer total hospital stays.
More severe patients had shorter total hospital stays,
probably due to higher mortality. Higher mortality was
associated with older patients and higher disease severity.
CONCLUSION: There is much discussion about treat-
ment guidelines and use of care plans to improve quality
of care and reduce hospitalization costs. In this study, the
type of sedation and analgesia treatment in mechanically
ventilated ICU patients and whether the patient had a
care plan did not influence days in ICU or mortality.
Whether following treatment guidelines and care plans
reduces total costs, needs further evaluation.
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A MODEL FOR COMPARING COSTS 
ASSOCIATED WITH PRESCRIPTION
WASTAGE WITH APPLICATION TO VA 
PRESCRIPTION DATA
Walton SM, Johnson NE, Arondekar BV, Schumock GT
University of Illinois at Chicago, Chicago, IL, USA
OBJECTIVE: The objective of this study was to deter-
mine the frequency and cost of prescription switches for
90-day vs. 30-day outpatient prescriptions dispensed by a
VA pharmacy and to develop a model to determine the
prescription fill policy with the lowest total costs.
METHODS: VA outpatient prescription records for one
year for simvastatin and lovastatin (30 or 90-days) were
analyzed to determine the frequency, quantity and cost of
medication wasted due to medication switches. The
quantity wasted was defined as the difference between
the quantity dispensed and the quantity of drug used be-
fore changing to a new drug or dosage. Differences in dis-
pensing costs for a given time-period were also included.
Sensitivity analyses were conducted for quantity wasted,
drug costs, and dispensing costs. RESULTS: A total of
16,990 prescriptions were analyzed. The quantity and
costs of medication wasted were higher for 90-day pre-
scriptions than for 30-day prescriptions. However, aver-
age costs to the VA pharmacy were $2.45 higher per pre-
scription for the 30-day supply because of additional
dispensing costs for the 30-day fill. The model and sensi-
tivity analyses show that a 90-day supply policy results in
lower total pharmacy costs under several scenarios. Only
in the case of high drug costs was the 30-day policy fa-
vorable to the 90-day policy in terms of total costs.
CONCLUSION: Prescriptions given in a 90-day supply
resulted in lower total costs. The projected cost savings of
having a 90-day versus a 30-day policy would hold true
for prescriptions with similar drug costs and similar rates
of wastage that result from changes that physicians make
to patients’ prescriptions. In addition, the model provides
a flexible framework for pharmacy administrators to as-
sess refill policies in terms of excess or unnecessary cost
for different classes of drugs, given patient and/or physi-
cian behavior.
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USING FINANCIAL RATIOS TO COMPARE 
PHARMACY SPENDING IN THE DEPARTMENT 
OF VETERANS AFFAIRS
Sampson JM
VA Medical Center, Alexandria, LA, USA
OBJECTIVE: To understand how pharmacy spending
varies across the VA Medical Centers in the United States.
Pharmacy costs continue to rise. From 1990 to 1994
pharmacy expenditures were reported to be 6% of the to-
tal Veteran’s Health Association (VHA) budget. In 1995
and 1996 it was 7%. In 1997 it was 8% and in 1998 it
was 9%. Then in 1999 it went to 11%. Future projections
are for a continued increase in budget spending. METH-
ODS: Ratios of yearly Pharmacy to Medical Center ex-
penditures were compared. These ratios were ranked and
compared with geographical location. The years of 1997
and 1998 were studied. RESULTS: The majority of the
highest ratios were located in the Midwest, Soutwest, and
Southern regions of the United States. CONCLUSIONS:
Financial ratios can demonstrate variations in expendi-
tures and identify areas that may require further inquiry.
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THE LAG BETWEEN EFFECTIVENESS AND 
COST-EFFECTIVENESS EVIDENCE OF NEW 
DRUGS AND DECISION-MAKING IN
HEALTH CARE
Stoykova BA, Drummond M, Kleijnen J
University of York, York, UK
BACKGROUND: A new drug is approved for use if its
effectiveness has been demonstrated. Recently decision-
makers in a number of countries have begun to account
for both the effectiveness and cost-effectiveness of new
drugs. However, cost-effectiveness evidence lags behind
the effectiveness data. OBJECTIVE: To explore the time-
liness of delivering cost-effectiveness information about
new drugs with established effectiveness and significant
financial impact. METHODS: New drugs were identi-
fied, based on guidance documents and reports published
by the National Institute for Clinical Excellence of En-
gland and Wales, and the following data were collected:
dates of publication of first effectiveness and cost-effec-
tiveness evidence, methodology of the cost-effectiveness
analysis, funding of the research, etc. RESULTS: Guid-
ance documents for the following new drugs/drug groups
have been published by NICE by the end of 2000: tax-
